Introduction
============

Current Scenario
----------------

Tuberculosis (TB) still remains one of the deadliest infectious diseases worldwide which is caused by *Mycobacterium tuberculosis.* WHO reported 10.4 million people became ill and that 1.8 million died from TB ([@B20]). For controlling this situation the available current tools are vaccine diagnostics and drugs. Over the past 50 years, the *Mycobacterium bovis* bacille Calmette--Guérin (BCG) vaccine against TB has maintained its position as the world's most widely used vaccine, despite showing highly variable efficacy (0--80%) in different trials ([@B1]).

Sputum smear microscopy is the most common TB diagnostic method worldwide. However, culture remains the gold standard and the use of rapid molecular testing like line probe assay (LPA) is increasing for detection of drug resistant *M. tuberculosis* strains. Recently in India, Revised National TB Control Program (RNTCP) has approved a study for the Validation of second line LPA for detecting resistance to fluoroquinolones, aminoglycosides (kanamycin, amikacin), and cyclic peptides (capreomycin). First and second line drugs are the effective and necessary component of short course chemotherapy. DOTS and DOTS plus program have reduced the incidence of TB caused by susceptible strain but emergence of multidrug-resistant tuberculosis (MDR-TB), extensively drug resistant tuberculosis (XDR-TB), and totally drug resistant tuberculosis (TDR-TB) have worsened the situation and became a major threat to public health. Current tools (vaccines, diagnostics, and therapeutics) are unable to offer the complete protection against these deadly drug resistant situations.

Mystery behind the Drug Resistance
----------------------------------

Usually interrupted anti-TB drugs treatment (first and second line anti-mycobacterial drugs) leads to emergence of drug resistant *M. tuberculosis* strains. Probably these resistant *M. tuberculosis* strains can resist antibiotic actions by the series of mechanisms such as: mutations in target genes ([@B2]), enzymatic inactivation of antibiotic molecules ([@B19]), over expression of novel efflux pumps and porin alterations in the cell wall ([@B7]; [@B9]), trapping of drugs and the over expression of proteins involved in neutralizing the effect of drugs ([@B8]; [@B4]; [@B5]; [@B12], [@B15]). Genes involved in these drug resistance mechanisms are tabulated in **Table [1](#T1){ref-type="table"}** (adopted from [@B21] and updated). **Figure [1](#F1){ref-type="fig"}** is the schematic diagram which showed the potential mechanism (s) of action of first line (Rifampicin-inhibition of RNA synthesis, Isoniazid-inhibition of mycolic acid biosynthesis, Ethambutol-inhibition of arabinogalactan synthesis, Pyrazinamide-depletion of membrane energy, and Streptomycin-inhibition of protein synthesis) and second line of anti-TB drugs (Amikacin, Kanamycin, Capreomycin-inhibition of protein synthesis and Quinolones-inhibition of DNA gyrase) and the potential mechanism (s) of drug resistance, respectively. These mechanisms of action of drugs were also tabulated in **Table [1](#T1){ref-type="table"}**. Usually 36--95% resistances in *M. tuberculosis* were contributed by mutations in the target genes, however, remaining 5--64% does not have these mutations and signifying the contribution of some other resistance mechanism (s). Research through expression proteomics (2D gel electrophoresis) and bioinformatic tools (like molecular docking, pupylation, and proteins-proteins interaction) explored the other novel mechanisms of drug resistance were accumulated in last decade and still underway. Patch dock and fire dock (molecular docking) predicted, drug binds to the conserved domain of the hypothetical proteins and suggested that overexpression of these proteins of undefined role might be neutralize/modulate the effects of drugs ([@B12], [@B15]). Pupylation is a post translational modification through which small disordered protein Pup is conjugated to lysine residues of proteins marking them for proteasomal degradation. GPS-PUP (pupylation) predicted, that neutralized/modulated adduct (drug-protein complex) might be degraded by proteasome machinery complex {turnover of the proteins} ([@B12], [@B15]). As modification with pup is reversible, pupylation is also likely to have a regulatory role. Pup-proteasome system controlled by pupylation contributes to the virulence/survival strategy of *M. tuberculosis* in the host and makes the bacteria more resistant to various stresses. STRING-10 (Proteins-proteins interaction) predicted the potential interactive partners and suggested the metabolic pathways involved in resistance ([@B14],[@B15]). Rv0148 (hypothetical protein/putative short-chain type dehydrogenase/reductase) was overexpressed in aminoglycosides resistant *M. tuberculosis* and had conserved SDR domain. We found that aminoglycosides binds to SDR domains and might be neutralized the drug effect ([@B12]). Further we characterized it and found that overexpression of Rv0148 involved in shift in MIC of aminoglycosides in recombinant *E. coli* ([@B13]). These findings might be used in the development of newer therapeutic agents or molecular markers which can directly be targeted to a gene/protein responsible for resistance. In this work we discuss the probable involvement of uncharacterized/hypothetical proteins (differential expression in drug resistance studies were previously reported) in drug resistance via bioinformatics analysis (like molecular docking, pupylation, and proteins-proteins interaction) and suggested that these might be explore novel mechanism of drug resistance or used as potential future drug target/diagnostics against drug resistance.

###### 

Mechanisms of genes involved in drug resistance in *Mycobacterium tuberculosis.*

  Drug (Year of discovery)                      MIC (μg/ml)       Gene (s) involved in resistance   Gene-product                                            Mechanism of action                                                  Mutation frequency %
  --------------------------------------------- ----------------- --------------------------------- ------------------------------------------------------- -------------------------------------------------------------------- ----------------------
  Isoniazid, 1952                               0.02--0.2         *kat*G*inh*A                      Catalase-peroxidase Enoyl ACP reductase                 Inhibition of mycolic acid biosynthesis and other multiple effects   50--95 8--43
  Rifampicin, 1966                              0.05--1           *rpo*B                            β-subunit of RNA polymerase                             Inhibition of RNA synthesis                                          95
  Pyrazinamide, 1952                            16--50 (pH 5.5)   *pnc*A                            Nicotinamidase/pyrazinamidase                           Depletion of membrane energy                                         72--97
  Ethambutol, 1961                              1--5              *emb*B                            Arabinosyl transferase                                  Inhibition of arabinogalactan synthesis                              47--65
  Streptomycin, 1944                            2--8              *rps*L*rrs gid*B                  S12 ribosomal protein 16S rRNA rRNA methyltransferase   Inhibition of protein synthesis                                      52--59 8--21 ?
  Amikacin Kanamycin, 1957; Capreomycin, 1960   2--4              *Rrs tly*A                        16S rRNA 2′-*O*-methyltransferases                      Inhibition of protein synthesis                                      76
  Quinolones, 1963                              0.5--2.5          *gyr*A*gyr*B                      DNA gyrase subunit A DNA gyrase subunit B               Inhibition of DNA gyrase                                             75--94
  Ethionamide, 1956                             2.5--10           *eth*A                            Flavin monooxygenase                                    Inhibition of mycolic acid synthesis                                 37
  PAS, 1946                                     1--8              *thy*A                            Thymidylate synthase                                    Inhibition of folic acid synthesis and iron metabolism               36
  Bedaquiline, 2012                             0.125--0.50       *atp*E                            ATP synthase                                            Block the proton pump for ATP synthesis                              ?

MIC, minimum inhibitory concentration; ACP, acyl carrier protein; PAS, Para-aminosalicylic acid.

![**Schematic diagram showed: (A)** Potential mechanism (s) of action of first and second line of anti-TB drugs. **(B)** Potential mechanism (s) of drug resistance in *Mycobacterium tuberculosis.*](fmicb-08-00465-g001){#F1}

Expression Proteomics and Bioinformatics Approaches: A Way for Exploring the Mystery of Drug Resistance
-------------------------------------------------------------------------------------------------------

Advancement in proteomics has explored the mystery behind any complex phenotypes like drug resistance. As proteins manifest most of the biological processes, these are attractive targets for exploring new mechanisms of the drug resistance. Expression proteomics (2-DE coupled with MALDI-TOF-MS) and bioinformatic tools {patch dock and fire dock for molecular docking, GPS-PUP for pupylation, and STRING-10 for protein-protein interaction} have now emerged as major analytical tools for identification and characterization of expression proteome (proteins and its species) ([@B12]; [@B10]). In the last decade (2006--2016) few reports on expression proteome of drugs resistant *M. tuberculosis* existed ([@B3]; [@B17], [@B16], [@B13], [@B15]; [@B4]; [@B5],[@B6]; [@B18]; [@B11]) and suggested that differential expression of functionally known and unknown proteins and their protein-protein interaction might be involved in resistance and could be explore the novel mechanism of resistance.

Hypothetical Proteins and Proteins of Unknown Function: Potential Targets of Drug Resistance or Novel Resistance Mechanisms
===========================================================================================================================

Since last decade, few proteomics and bioinformatics studies of drug resistant *M. tuberculosis* have been accumulated and reported the differential expression of a panel of uncharacterized (proteins of unknown function) and hypothetical proteins. Through *in silico*/bioinformatic (Interproscan and molecular docking) analysis they showed that drugs binds to the conserved domains of hypothetical proteins/uncharacterized proteins and suggested that the over expression of a panel of uncharacterized and hypothetical proteins might neutralize/compensate the effect of drugs. [@B13], [@B14]) reported that inducible over expression of cloned known and unknown proteins (Rv0148 and Rv3841) in *E. coli* makes it two- to threefolds more resistant under drug pressure. Here we emphasize that detailed bioinformatics analysis (like protein-protein interaction) of these uncharacterized and hypothetical proteins might predict their interactive partners (other proteins) which are involved in various pathways of *M. tuberculosis* system biology (exploring/deciphering the *M. tuberculosis* network biology through *in silico*/holistic approaches) and might give a clue for novel mechanism of drug resistance or future target. Research in this direction could prevent the emergence of MDR-TB, XDR-TB, and TDR-TB situation and also these targets may be used to discover the new drug entities as potential drug candidates against drug resistant tuberculosis.

Conclusion and Future Perspective
=================================

Based on the evidence discussed above related to expression proteomics and bioinformatics studies of drug resistant *M. tuberculosis* have been reported the differential expression of uncharacterized and hypothetical proteins ([@B3]; [@B17], [@B16], [@B13], [@B15]; [@B4]; [@B5]; [@B18]; [@B11]). Molecular docking analysis of these uncharacterized and hypothetical proteins suggested that their over expression might neutralize/compensate the effect of drugs ([@B17], [@B12], [@B15]; [@B4]; [@B5]; [@B11]) which further proved by other reports and showed inducible over expression of cloned known and unknown proteins in *E. coli* which makes it few folds more resistant under drug pressure ([@B13]). Here we emphasized the detailed *in silico* analysis through patch dock, fire dock (molecular docking), GPS-PUP (pupylation), and STRING-10 (predicts the proteins-proteins interactions/interactome) of these uncharacterized and hypothetical proteins which might be involved in various pathways of *M. tuberculosis* system biology ([@B5]; [@B12], [@B15]; [@B11]). Future research in this direction could be uncovering the novel mechanism of drug resistance or future target. Which ultimately prevent the emergence of deadly resistant strains of *M. tuberculosis* and could leads to discovery of the new drug entities against deadly drug resistant tuberculosis.
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